The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Public ClinicalTrials.gov record NCT00159861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimised Dose of Sildenafil Citrate (20, 40, or 80 mg. Sildenafil Citrate TID) Based on the Toleration, When Used in Combination With Intravenous Prostacyclin( Epoprostenol) in the Treatment of Pulmonary Arterial Hypertension.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
Study identification
- NCT ID
- NCT00159861
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 267 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2003
- Primary completion
- Not listed
- Completion
- Dec 31, 2005
- Last update posted
- Jan 31, 2021
2003 – 2006
United States locations
- U.S. sites
- 33
- U.S. states
- 20
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | Los Angeles | California | 90073 | — |
| Pfizer Investigational Site | San Diego | California | 92103 | — |
| Pfizer Investigational Site | Torrance | California | 90502 | — |
| Pfizer Investigational Site | Torrance | California | 90509 | — |
| Pfizer Investigational Site | Denver | Colorado | 80220 | — |
| Pfizer Investigational Site | Denver | Colorado | 80262 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60637 | — |
| Pfizer Investigational Site | Kansas City | Kansas | 66160 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70112 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21287 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02111 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02114 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68105 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68198-2125 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267-0769 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Pfizer Investigational Site | Providence | Rhode Island | 02903 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232-5735 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84143 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53215 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53226 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53277 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00159861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 31, 2021 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00159861 live on ClinicalTrials.gov.